Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Capmatinib + Nazartinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Capmatinib||Tabrecta||INC280|INC-280|INCB028060|INCB28060|INCB 28060||MET Inhibitor 51||Tabrecta (capmatinib) inhibits MET signaling and may induce cell death in tumors overexpressing MET or expressing constitutively activated MET (PMID: 31853265). Tabrecta (capmatinib) is FDA approved for use in patients with metastatic non-small cell lung cancer harboring MET exon 14 skipping mutations (FDA.gov).|
|Nazartinib||EGF816|EGF-816||EGFR Inhibitor 3rd gen 20||Nazartinib (EGF816) is a third generation EGFR inhibitor with selectivity towards mutant forms of EGFR, resulting in inhibition of tumor cell growth (PMID: 27433829, PMID: 31954624).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03333343||Phase I||LXH 254 + Nazartinib Nazartinib + Trametinib Gefitinib + Nazartinib Nazartinib + Ribociclib Capmatinib + Nazartinib||Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC||Recruiting|
|NCT02335944||Phase Ib/II||Capmatinib + Nazartinib||Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Non-small Cell Lung Cancer Patients With EGFR Mutation.||Active, not recruiting|
|NCT03040973||Phase II||Capmatinib + Nazartinib Capmatinib Capmatinib + Gefitinib||Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving INC280 Treatment as Single Agent or in Combination With Other Treatments.||Recruiting|